In the BioHarmony Drug Report Database
Solriamfetol
Sunosi (solriamfetol) is a small molecule pharmaceutical. Solriamfetol was first approved as Sunosi on 2019-06-17. It is used to treat sleepiness in the USA. It has been approved in Europe to treat narcolepsy and obstructive sleep apnea. It is known to target sodium-dependent dopamine transporter and sodium-dependent noradrenaline transporter. Sunosi’s patents are valid until 2040-03-19 (FDA).
Trade Name
|
Sunosi |
|---|---|
Common Name
|
solriamfetol |
ChEMBL ID
|
CHEMBL4297620 |
Indication
|
narcolepsy, obstructive sleep apnea, sleepiness |
Drug Class
|
Norepinephrine–dopamine reuptake inhibitors |
Image (chem structure or protein)